Question · asked by 1 review
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy: Serious adverse events
- Population
- people without inhibitors
- Intervention
- Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis
- Comparison
- on‐demand therapy
- Outcome
- Serious adverse events
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis vs on‐demand therapy Serious adverse events · people without inhibitors Summary of findings table ‐ Emicuzimab 1.5 mg/kg weekly prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty). Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane Headline outcomes only | RR 0.5 [0.03, 7.54] | 1 study · 54 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.